Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kangfuxin lozenge in recurrent aphthous ulcer (yin deficiency fire excess pattern)
CTR20182216Phase 2Suspended
- Sponsor
- Jingxin Pharmaceutical
- Start
- Dec 2018
- Countries
- 1
01
Overview
A Phase 2 trial of Kangfuxin lozenge in aphthosis (RAS), sponsored by Jingxin Pharmaceutical. Started Dec 2018; status: suspended.
02
Drugs
Kangfuxin lozenge
03
Conditions
aphthosis (RAS)
Beyond the preview
Go deeper on CTR20182216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182216.